Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Trial of Anti-CD20 in C4d+ Chronic Allograft Nephropathy

Trial Profile

Randomised Trial of Anti-CD20 in C4d+ Chronic Allograft Nephropathy

Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms RituxiCAN-C4
  • Most Recent Events

    • 15 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 09 Jan 2017 Planned End Date changed from 1 Jan 2018 to 1 Apr 2017.
    • 04 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top